O
ALXN

OrbiMed’s Alexion Pharmaceuticals ALXN Stock Holding History

OrbiMed’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-150,900
Closed -$27.7M – 189
2021
Q2 		$27.7M Buy
150,900
+48,800
+48% +$8.38M 0.28% 85
2021
Q1 		$15.6M Sell
102,100
-66,900
-40% -$10.3M 0.15% 107
2020
Q4 		$26.4M Sell
169,000
-2,015,500
-92% -$259M 0.23% 88
2020
Q3 		$250M Buy
2,184,500
+28,500
+1% +$3.07M 3.14% 4
2020
Q2 		$242M Buy
2,156,000
+84,615
+4% +$8.98M 3.41% 3
2020
Q1 		$186M Buy
2,071,385
+408,800
+25% +$40.1M 3.13% 6
2019
Q4 		$180M Sell
1,662,585
-700
-0% -$74.9K 2.57% 8
2019
Q3 		$163M Sell
1,663,285
-262,800
-14% -$29.6M 3.09% 7
2019
Q2 		$252M Sell
1,926,085
-31,115
-2% -$4.01M 3.91% 4
2019
Q1 		$265M Sell
1,957,200
-90,200
-4% -$11.2M 4.1% 4
2018
Q4 		$199M Sell
2,047,400
-833,703
-29% -$98.5M 3.69% 6
2018
Q3 		$401M Sell
2,881,103
-243,500
-8% -$30.5M 4.82% 1
2018
Q2 		$388M Sell
3,124,603
-143,672
-4% -$16.8M 4.63% 1
2018
Q1 		$364M Buy
3,268,275
+388,700
+13% +$46.5M 4.52% 1
2017
Q4 		$344M Sell
2,879,575
-765,911
-21% -$93.3M 4.36% 2
2017
Q3 		$511M Sell
3,645,486
-226,300
-6% -$30.7M 4.89% 1
2017
Q2 		$471M Buy
3,871,786
+160,800
+4% +$18.7M 4.94% 1
2017
Q1 		$450M Buy
3,710,986
+322,600
+10% +$41.6M 5.1% 1
2016
Q4 		$415M Buy
3,388,386
+750,375
+28% +$91.8M 5.28% 1
2016
Q3 		$323M Sell
2,638,011
-343,400
-12% -$44.2M 3.68% 4
2016
Q2 		$348M Buy
2,981,411
+1,110,811
+59% +$158M 3.63% 6
2016
Q1 		$260M Sell
1,870,600
-404,500
-18% -$59.4M 2.74% 10
2015
Q4 		$434M Buy
2,275,100
+48,500
+2% +$8.47M 3.93% 8
2015
Q3 		$348M Buy
2,226,600
+182,200
+9% +$33.2M 3.52% 9
2015
Q2 		$370M Buy
2,044,400
+1,478,700
+261% +$255M 3.09% 9
2015
Q1 		$98M Buy
565,700
+233,700
+70% +$42.3M 0.84% 38
2014
Q4 		$61.4M Buy
332,000
+20,000
+6% +$3.71M 0.59% 43
2014
Q3 		$51.7M Hold
312,000
– – 0.54% 46
2014
Q2 		$48.8M Buy
312,000
+45,000
+17% +$7.11M 0.57% 46
2014
Q1 		$40.6M Buy
267,000
+34,100
+15% +$5.42M 0.5% 47
2013
Q4 		$30.9M Buy
232,900
+17,000
+8% +$2.04M 0.45% 49
2013
Q3 		$25.1M Buy
215,900
+23,000
+12% +$2.52M 0.45% 49
2013
Q2 		$17.8M Buy
+192,900
New +$18.6M 0.38% 54

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

OrbiMed's ALXN Position: Q3 2021 in Review

OrbiMed sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 150,900 shares — an estimated $27.7M sold.

OrbiMed first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $511M in Q3 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • OrbiMed reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • OrbiMed sold 150,900 Alexion Pharmaceuticals shares in Q3 2021, an estimated $27.7M.
  • OrbiMed first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • OrbiMed's Alexion Pharmaceuticals position peaked at $511M in Q3 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.